TY  - BOOK
AU  - Shereen Hamdi Noshi
AU  - Hussein Osman Ammar , 
AU  - Mahmoud Mohamed Ghorab , 
TI  - Gastroretentive system for delivering an antipsychotic drug / 
PY  - 2015///
CY  - Cairo : 
PB  - Shereen Hamdi Noshi , 
KW  - Antipsychotic drug
KW  - Gastroretentive system
KW  - Pharmaceutics
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics; Issued also as CD
N2  - Schizophrenia is a severe and disabling mental illness. It affects approximately 1% of the population worldwide and it is a chronic, severe  disorder, lacking curative treatment. The suicide rate is as high as 9 - 13%, with the incidence of suicide attempt reaching 50% of diagnosed patients over a lifetime. The onset of schizophrenia usually occurs around 18 -  25 years of age and is often preceded by premorbid behavioural deviations, such as social withdrawal and affective changes. The symptoms and severity can vary over individual with schizophrenia. The symptoms are commonly divided into three  categories, namely, positive symptoms, negative symptoms and cognitive deficits. Antipsychotics can be broadly classified into first generation  antipsychotics (FGAs, formerly known as {u2018}typical{u2019} antipsychotics) and second generation antipsychotics (SGAs, formerly known as {u2018}atypical{u2019} antipsychotics). First - generation antipsychotics are as effective as second - generation drugs in treating the 2positive3 symptoms of schizophrenia, such as hallucinations, delusions, and paranoia, although they vary in  their propensity to cause side effects
ER  -